JP6033433B2 - アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法 - Google Patents

アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法 Download PDF

Info

Publication number
JP6033433B2
JP6033433B2 JP2015524242A JP2015524242A JP6033433B2 JP 6033433 B2 JP6033433 B2 JP 6033433B2 JP 2015524242 A JP2015524242 A JP 2015524242A JP 2015524242 A JP2015524242 A JP 2015524242A JP 6033433 B2 JP6033433 B2 JP 6033433B2
Authority
JP
Japan
Prior art keywords
apolipoprotein
pharmaceutical composition
protein
apo
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015524242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524432A (ja
JP2015524432A5 (enExample
Inventor
ソウ，パトリック
ワーン，フェイ
デーヴィッドソン，ショーン
ウッズ，スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2015524432A publication Critical patent/JP2015524432A/ja
Publication of JP2015524432A5 publication Critical patent/JP2015524432A5/ja
Application granted granted Critical
Publication of JP6033433B2 publication Critical patent/JP6033433B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015524242A 2012-07-25 2012-11-21 アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法 Expired - Fee Related JP6033433B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675549P 2012-07-25 2012-07-25
US61/675,549 2012-07-25
PCT/US2012/066334 WO2014018079A1 (en) 2012-07-25 2012-11-21 Method of treating hyperglycemic disorders using apoliprotein aiv

Publications (3)

Publication Number Publication Date
JP2015524432A JP2015524432A (ja) 2015-08-24
JP2015524432A5 JP2015524432A5 (enExample) 2016-01-21
JP6033433B2 true JP6033433B2 (ja) 2016-11-30

Family

ID=47295208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524242A Expired - Fee Related JP6033433B2 (ja) 2012-07-25 2012-11-21 アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法

Country Status (5)

Country Link
US (1) US10232019B2 (enExample)
JP (1) JP6033433B2 (enExample)
AU (1) AU2012385960B2 (enExample)
CA (1) CA2878684A1 (enExample)
WO (1) WO2014018079A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US9730980B2 (en) 2012-07-25 2017-08-15 University Of Cincinnati Method of treating type I diabetes using apolipoprotein A-IV

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
PL374126A1 (en) 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103788043B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014011908A1 (en) * 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9730980B2 (en) 2012-07-25 2017-08-15 University Of Cincinnati Method of treating type I diabetes using apolipoprotein A-IV

Also Published As

Publication number Publication date
CA2878684A1 (en) 2014-01-30
US10232019B2 (en) 2019-03-19
WO2014018079A8 (en) 2015-01-22
WO2014018079A9 (en) 2015-03-12
AU2012385960A1 (en) 2015-02-05
AU2012385960B2 (en) 2017-04-13
JP2015524432A (ja) 2015-08-24
WO2014018079A1 (en) 2014-01-30
US20150182591A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP6310398B2 (ja) 非グリコシル化アポリポタンパク質ａ−ｉｖを用いて糖尿病を処置する方法
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
JP7360751B2 (ja) ＦＧＦ２１ Ｆｃ融合タンパク質、ＧＬＰ－１ Ｆｃ融合タンパク質、それらの併用治療剤および使用
US9266941B2 (en) Apolipoprotein AIV as an antidiabetic peptide
JP6033433B2 (ja) アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
US9730980B2 (en) Method of treating type I diabetes using apolipoprotein A-IV
JP2008546816A (ja) エキセンディン４ポリペプチドフラグメントおよびその使用
JP5121400B2 (ja) 筋ジストロフィ治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150327

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20150323

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20150422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161025

R150 Certificate of patent or registration of utility model

Ref document number: 6033433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees